Assessing long-term effectiveness and cost-effectiveness of statin therapy in the UK: a modelling study using individual participant data sets

Cardiovascular disease has declined but remains a major disease burden across developed countries. To assess the effectiveness and cost-effectiveness of statin therapy across United Kingdom population categories. The cardiovascular disease microsimulation model, developed using Cholesterol Treatment...

Full description

Saved in:
Bibliographic Details
Published in:Health technology assessment (Winchester, England) England), 2024-12, Vol.28 (79), p.1-134
Main Authors: Mihaylova, Borislava, Wu, Runguo, Zhou, Junwen, Williams, Claire, Schlackow, Iryna, Emberson, Jonathan, Reith, Christina, Keech, Anthony, Robson, John, Parnell, Richard, Armitage, Jane, Gray, Alastair, Simes, John, Baigent, Colin
Format: Article
Language:English
Subjects:
Adult
Aged
cardiovascular diseases
Cardiovascular Diseases - prevention & control
Cost-Benefit Analysis
cost-effectiveness analysis
decision support techniques
decision-analytic model
Female
Humans
hydroxymethylglutaryl-coa reductase inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Male
Middle Aged
Quality of Life
Quality-Adjusted Life Years
United Kingdom
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cardiovascular disease has declined but remains a major disease burden across developed countries. To assess the effectiveness and cost-effectiveness of statin therapy across United Kingdom population categories. The cardiovascular disease microsimulation model, developed using Cholesterol Treatment Trialists' Collaboration data and the United Kingdom Biobank cohort, projected cardiovascular events, mortality, quality of life and healthcare costs using participant characteristics. United Kingdom primary health care. A total of 117,896 participants in 16 statin trials in the Cholesterol Treatment Trialists' Collaboration; 501,854 United Kingdom Biobank participants by previous cardiovascular disease status, sex, age (40-49, 50-59 and 60-70 years), 10-year cardiovascular disease risk [QRISK 3 (%):
ISSN:2046-4924
1366-5278
2046-4924
DOI:10.3310/KDAP7034